Furthermore, studies on the IBC tumor microenvironment [13,14,22,23,24,25], including our previous studies [26], provide evidence for immune responses toward IBC, suggesting that patients may benefit from immune checkpoint inhibitors (ICI), such as PD-1/PD-L1 blocking antibodies. Here, CD274 is linked to inflammatory breast carcinoma.